These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 15587503)

  • 21. The role of FXR in disorders of bile acid homeostasis.
    Eloranta JJ; Kullak-Ublick GA
    Physiology (Bethesda); 2008 Oct; 23():286-95. PubMed ID: 18927204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nuclear receptors as potential drug targets in osteoarthritis.
    Sun MM; Beier F; Ratneswaran A
    Curr Opin Pharmacol; 2018 Jun; 40():81-86. PubMed ID: 29626714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma.
    Giri S; Rattan R; Singh AK; Singh I
    J Immunol; 2004 Oct; 173(8):5196-208. PubMed ID: 15470065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy.
    Patel HJ; Belvisi MG; Bishop-Bailey D; Yacoub MH; Mitchell JA
    J Immunol; 2003 Mar; 170(5):2663-9. PubMed ID: 12594295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Nuclear receptors-ligands, cofactors and target genes].
    Inoue S
    Nihon Ronen Igakkai Zasshi; 2000 Apr; 37(4):265-70. PubMed ID: 10917021
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation.
    Ram VJ
    Prog Drug Res; 2003; 60():93-132. PubMed ID: 12790340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PPARs and LXRs: atherosclerosis goes nuclear.
    Barish GD; Evans RM
    Trends Endocrinol Metab; 2004; 15(4):158-65. PubMed ID: 15109614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isoprostane activation of the nuclear hormone receptor PPAR.
    McNamara P; Lawson JA; Rokach J; FitzGerald GA
    Adv Exp Med Biol; 2002; 507():351-5. PubMed ID: 12664609
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of fatty acids on gene expression mediated by a member of the nuclear receptor supergene family.
    Gustafsson JA; Gearing K; Widmark E; Tollet P; Strömstedt M; Berge RK; Göttlicher M
    Prog Clin Biol Res; 1994; 387():21-8. PubMed ID: 7972247
    [No Abstract]   [Full Text] [Related]  

  • 30. Molecular targets for the treatment of fibrosing cholangiopathies.
    Maillette de Buy Wenniger LJ; Oude Elferink RP; Beuers U
    Clin Pharmacol Ther; 2012 Sep; 92(3):381-7. PubMed ID: 22850600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Endocrine disruptors and nuclear receptors].
    Watanabe H; Iguchi T; Morohashi K
    Nihon Rinsho; 2002 Feb; 60(2):397-403. PubMed ID: 11857933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Changing paradigms in dermatology: nuclear hormone receptors.
    Winterfield L; Cather J; Cather J; Menter A
    Clin Dermatol; 2003; 21(5):447-54. PubMed ID: 14678724
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors.
    El-Sankary W; Plant NJ; Gibson GG; Moore DJ
    Drug Metab Dispos; 2000 May; 28(5):493-6. PubMed ID: 10772626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear receptors, bile-acid detoxification, and cholestasis.
    Chen J; Raymond K
    Lancet; 2006 Feb; 367(9509):454-6. PubMed ID: 16473109
    [No Abstract]   [Full Text] [Related]  

  • 35. Peroxisome proliferator-activated receptor gamma agonists: potential use for treating chronic inflammatory diseases.
    Oates JC; Reilly CM; Crosby MB; Gilkeson GS
    Arthritis Rheum; 2002 Mar; 46(3):598-605. PubMed ID: 11920394
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of tryptophan related compounds on nuclear regulatory control. Possible role in the eosinophilia-myalgia syndrome.
    Sidransky H; Verney E; Latham P; Schwartz A
    Adv Exp Med Biol; 1996; 398():343-50. PubMed ID: 8906287
    [No Abstract]   [Full Text] [Related]  

  • 37. COX-2 and cancer: a new approach to an old problem.
    Bakhle YS
    Br J Pharmacol; 2001 Nov; 134(6):1137-50. PubMed ID: 11704632
    [No Abstract]   [Full Text] [Related]  

  • 38. Synthesis and biological activity of adenophostin derivatives as IP3 receptor ligands.
    Shuto S; Mochizuki T; Abe H; Kondo Y; Matsuda A
    Nucleic Acids Res Suppl; 2002; (2):23-4. PubMed ID: 12903086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease.
    Fuchs CD; Traussnigg SA; Trauner M
    Semin Liver Dis; 2016 Feb; 36(1):69-86. PubMed ID: 26870934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate.
    Mirshahpanah P; Döcke WD; Merbold U; Asadullah K; Röse L; Schäcke H; Zollner TM
    Exp Dermatol; 2007 Sep; 16(9):753-61. PubMed ID: 17697148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.